VEGFA and glioblastoma: Over the past 30 years, Food and Drug Administration (FDA) proposed only four medications for the GBM therapy, such as lomustine, carmustine, temozolomide (TMZ), which are alkylating agents, and bevacizumab (BZM), which is a monoclonal antibody preventing activation the vascular endothelial growth factor (VEGF) and dfi 2emonstrating antiangiogenic effects (8–10).